TScan Therapeutics (TCRX) Projected to Post Quarterly Earnings on Wednesday

TScan Therapeutics (NASDAQ:TCRX) is expected to release its Q4 2025 results before the market opens on Wednesday, March 4th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

TScan Therapeutics Price Performance

Shares of NASDAQ TCRX opened at $1.05 on Wednesday. The stock has a market cap of $59.59 million, a P/E ratio of -0.94 and a beta of 1.04. TScan Therapeutics has a twelve month low of $0.88 and a twelve month high of $2.57. The stock has a 50 day moving average of $1.04 and a two-hundred day moving average of $1.43. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23.

Wall Street Analyst Weigh In

TCRX has been the topic of a number of recent research reports. HC Wainwright cut their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a report on Thursday, January 22nd. Needham & Company LLC decreased their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Finally, BTIG Research lowered TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.60.

Insiders Place Their Bets

In related news, major shareholder Lynx1 Capital Management Lp bought 80,069 shares of the stock in a transaction on Friday, December 19th. The shares were bought at an average cost of $0.90 per share, for a total transaction of $72,062.10. Following the completion of the transaction, the insider owned 7,937,416 shares of the company’s stock, valued at $7,143,674.40. This represents a 1.02% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought 161,801 shares of company stock worth $145,621 in the last quarter. Corporate insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

Several institutional investors have recently modified their holdings of TCRX. Marshall Wace LLP purchased a new position in TScan Therapeutics in the 2nd quarter valued at approximately $78,000. Virtu Financial LLC grew its holdings in TScan Therapeutics by 431.1% in the third quarter. Virtu Financial LLC now owns 60,480 shares of the company’s stock valued at $110,000 after purchasing an additional 49,092 shares during the last quarter. Militia Capital Partners LP purchased a new position in shares of TScan Therapeutics in the second quarter valued at $137,000. Bridgeway Capital Management LLC raised its stake in shares of TScan Therapeutics by 35.7% during the 2nd quarter. Bridgeway Capital Management LLC now owns 153,700 shares of the company’s stock worth $223,000 after buying an additional 40,400 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock worth $235,000 after buying an additional 9,676 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.